Purdue Foundry

FOUNDERS

Pedro P. Irazoqui

Co-Founder

Prof. Irazoqui is professor and associate head of the Weldon School of Biomedical Engineering and professor of the School of Electrical and Computer Engineering. He is the Director of Purdue’s Center for Implantable Devices and a Showalter Faculty Scholar. His group develops wireless implantable devices for various potential applications including monitoring and suppression of epileptic seizures; prosthesis control for injured military personnel; modulation of cardiac arrhythmias; treatment of depression, and gastroparesis, a partial paralysis of the stomach; and monitoring and therapeutic modulation of intraocular pressure for glaucoma.

Simon John

Co-Founder & Researcher

Simon John is an internationally recognized biomedical researcher with expertise in genetics, physiology and ocular disease. With >30 years of experience, he is a leader in glaucoma research with a wealth of prestigious honors including the Bressler Award and Lewis Rudin Glaucoma Prize (3 times). He has a joint honors BSc in zoology and genetics from University College Cardiff, Wales and a PhD in biology and human genetics from McGill University, Canada. His postdoctoral training was with Nobel laureate Dr. Oliver Smithies at UNC, Chapel Hill. He is currently Investigator of the Howard Hughes Medical Institute and Professor at The Jackson Laboratory, Bar Harbor, Maine. (see www.simonjohnlab.org)

Doug Adams

Co-Founder & Chief Executive Officer

Doug Adams is a medical device industry executive with comprehensive medical and surgical industry experience. He currently serves as Co-Founder and CEO of QURA, a developmental stage medical device company focused on patient monitoring and digital health. Mr. Adams has thirty years of global experience in executive management, sales and marketing, business development, finance, and operations in the healthcare industry. He has directed the launch of twenty products in the ophthalmology and dermatology market and multiple start-ups. Mr. Adams has consistently demonstrated the ability to develop innovative sales and marketing strategies designed to leverage market penetration for first of their kind products and technology.

PROFILE

The ability to constantly collect long-term physiological data without disturbing experimental animals remains a challenge. Additionally, the ability to collect such data in human patients in their normal lives is difficult. Collecting this long term data in very small compartments within an animal or human is an added challenge and is often impossible. QURA is developing a series of ultra-miniature implantable devices/tools that will overcome these challenges and allow long term monitoring within very small spaces. These miniaturized tools will have potential to transform physiologic monitoring in biomedicine and other applications. In the long term, we envision networks of smart, miniaturized tools that communicate and respond to each other in real time. Networked devices will interact to both monitor disease and administer timely treatments. The development of these devices has great potential to revolutionize both research abilities and human clinical treatment.

FUNDING PHASE

Series A

RAISED TO-DATE

$6,500,000